[Use of LHRH agonists in the treatment of advanced cancer of the prostate].
The present article focuses on the usefulness of the LHRH analogues in the treatment of prostate cancer. The Author analyzes analogue obtention by amino acid substitution of natural LHRH to obtain compounds that may be 100 times more potent than natural LHRH and whose t 1/2 reach 7.6 h. He reports that Prof. Schally (1970 Nobel Prize in Medicine) has recently demonstrated the existence of D-Trp-6-LHRH in tumoral cells; thus, the action of this analogue not only consists in decreasing the sex hormones to castration levels but it also has a direct action. However, further studies are warranted in order to elucidate the effects of the foregoing findings in the clinical setting. The reasons for resorting to surgical castration or castration by analogues in the treatment of advanced prostatic cancer are put forward.
Fretin
J
J
Servicio de Urología, Hospital de Creil, Francia.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006207:Half-Life; D006728:Hormones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013737:Testis / Q000187:drug effects / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism; D017329:Triptorelin Pamoate
D000970:Antineoplastic Agents; D006728:Hormones; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone
Utilización de agonistas de la LHRH en el tratamiento del cáncer de próstata avanzado.